The U.S. Food and Drug Administration (“FDA”) accepted Celcuity’s New Drug Application (“NDA”) and granted Priority Review with a Prescription ...

Perceptive Advisors purchased 203,881 Celcuity shares in the fourth quarter; the estimated trade value was $16.76 million based on average fourth-quarter pricing. Meanwhile, the quarter-end position ...

View Celcuity Inc. CELC stock quote prices, financial information, real-time forecasts, and company news from CNN.

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Celcuity, Inc. (CELC) been one of those stocks this year?

Celcuity's gedatolisib, a pan-PI3K/mTOR inhibitor for advanced breast cancer, shows strong early efficacy and is in pivotal Phase 3 trials, yet remains undervalued. The company has a healthy cash ...

If you are wondering whether Celcuity's current share price reflects its true worth, you are not alone. This article focuses squarely on what the numbers suggest about value. The stock last closed at ...

Celcuity is a clinical-stage biotechnology firm focused on innovative cancer diagnostics and targeted therapies, leveraging its CELsignia platform to identify and address specific cellular drivers of ...

David Dalvey sold 20,000 shares indirectly on Jan. 27, 2026 for a transaction value of ~$2.4 million, at a weighted average price of $120.03 per share. The transaction represented 18.18% of Dalvey’s ...

- Virtual Science Day to be held on September 21, 2023 from 10:00 a.m. – 12:00 p.m. ET MINNEAPOLIS, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (CELC), a clinical-stage biotechnology company ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...